Plasma cell-free DNA methylation classifiers (Galleri-style multi-cancer early detection...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-CFDNA-MCED-MULTI-CANCER-SCREENING |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-18 | actionability review required |
| Enfermedades | DIS-CRC |
| Fuentes | SRC-CIVIC |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-CFDNA-METHYLATION-MCED |
|---|---|
| Variante | Signatura de metilación de ADN libre de células — señal multicancerosa |
| Enfermedad | DIS-CRC |
| El nivel de ESCAT | IIIA |
| Resumen de las pruebas | Plasma cell-free DNA methylation classifiers (Galleri-style multi-cancer early detection / MCED) detect a cancer signal across 50+ tumour types with tissue-of-origin prediction. PATHFINDER (Schrag 2023) prospectively demonstrated feasibility (specificity ~99.5%, PPV ~38%) but MCED is NOT yet endorsed by USPSTF, NCCN, or ESMO as screening. SYMPLIFY (NHS, 2023) evaluated symptomatic-patient triage. DIS-CRC anchor reflects the best-characterized signal class; the assay is intentionally multi-cancer and not disease-specific. Research-level evidence (ESCAT IIIA / CIViC C); cannot replace established screening (FIT, colonoscopy, mammography, LDCT) per current guidance. |
Notas
STUB pending two-Co-Lead signoff. MCED (Grail Galleri, Exact Sciences Cancerguard, others) is positioned as an ADJUNCT to USPSTF-endorsed screening, NOT a replacement. Outside CHARTER §2 non-commercial scope to recommend any specific brand; render layer must surface "investigational / research-only" framing. No surveillance/screening Indication entity exists yet that ingests an MCED-positive signal — pending a future IND-MCED-POSITIVE-WORKUP entity scoped to coordinate tissue-of-origin workup (PET/CT, site-directed endoscopy/imaging) after a positive MCED call. Until that exists, indications: [] is intentional. Anchor disease set to DIS-CRC because GRAIL CCGA sub-study reported strong signal in CRC and CRC is the most clinically-tractable post-MCED workup target; the underlying assay is multi-cancer and a future multi-tumor index entity may be appropriate.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.